Andrew Östör talks about the results of KEEPsAKE 2, a phase 3 trial of risankizumab versus placebo in patients with psoriatic arthritis, and explores how the IL-23 inhibitor may impact clinical practice if approved by the regulatory authorities.
Robert Spiera discusses the phase 3 RESOLVE-1 findings for lenabasum in patients with diffuse cutaneous systemic sclerosis, highlighting the possible effects of background immunosuppressive therapy on outcome.
04-06-2021 | EULAR 2021 | Conference coverage | Video